BioVersys AG
SSIX:BIOV23.30
CHF
-1.50
(-6.05%)
ISIN
CH0210362643
Return %
Stock
S&P 500
1Y
-0.43
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CHF
•
in mil. unless spec.Working Capital
CHF
•
in mil. unless spec.Growth Rates
CHF
•
in mil. unless spec.Semi-annual Revenue
CHF
•
in mil. unless spec.Semi-annual Earnings Per Share
CHF
•
in mil. unless spec.Semi-annual Dividends Per Share
CHF
•
in mil. unless spec.Company Description
- CEO
- Marc Gitzinger
- Full Time Employees
- 33
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Basel Switzerland
- IPO Date
- Feb 7, 2025
- Website
- bioversys.com
- Similar Companies
- Business
- BioVersys AG is a clinical-stage biopharmaceutical company that focuses on the research, development, and commercialization of small molecule therapeutics designed to overcome antimicrobial resistance and treat severe, life-threatening bacterial infections. The company leverages its proprietary Transcriptional Regulator Inhibitory Compounds (TRIC) platform to switch off bacterial resistance mechanisms and restore susceptibility to existing and novel antibiotics. Its development pipeline comprises BV100, an intravenous formulation of rifabutin in Phase 2 clinical development targeting carbapenem-resistant Acinetobacter baumannii (CRAB) infections, including hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and bloodstream infections; BVL-GSK098 (alpibectir), a small molecule transcriptional regulator inhibitor developed in collaboration with GlaxoSmithKline in Phase 2 clinical studies to enhance ethionamide efficacy for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis; BV200, a preclinical program targeting transcriptional regulators that control virulence and biofilm formation in Staphylococcus aureus; and BV300, a broad-spectrum small molecule discovery program targeting Gram-negative bacterial pathogens. The company primarily targets hospital care, intensive care units, and global public health markets. Founded in 2010 as a spin-off from ETH Zurich, BioVersys AG is headquartered in Basel, Switzerland, with clinical trial operations across Europe, North America, and South Africa. In recent developments, BioVersys AG expanded its Series C financing round with substantial backing from the AMR Action Fund and secured a venture loan facility from the European Investment Bank to accelerate the clinical progression of its lead assets; advanced Phase 2 patient trials for BV100 in target CRAB infections; achieved clinical milestones in its tuberculosis partnership with GSK; and extended non-dilutive grant funding partnerships with CARB-X and the Wellcome Trust to support preclinical and clinical-stage anti-infective programs.